Wen-Chi Yang1, Chung-Ho Chen2, Jen-Yang Tang3, Chih-Fung Wu4, Yi-Chang Liu5, Youping Sun6, Sheng-Fung Lin7. 1. Division of Hematology and Medical Oncology, Department of Internal Medicine, Yuan's General Hospital, Kaohsiung, Taiwan, R.O.C. Molecular Medicine Lab, Yuan's General Hospital, Kaohsiung, Taiwan, R.O.C. 2. Division of Oral Maxillofacial Surgery, Department of Dentistry, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C. 3. Department of Radiation Oncology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C. 4. Division of Surgical Oncology, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C. 5. Division of Hematology and Medical Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C. 6. Department of Radiation Oncology, Columbia University College of Physicians and Surgeons, New York, NY, U.S.A. 7. Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, R.O.C. Division of Hematology and Medical Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan, R.O.C. shlin@kmu.edu.tw.
Abstract
BACKGROUND: Locally recurrent rate of advanced head and neck squamous cell carcinoma (HNSCC) still remains high and the treatment is controversial. PATIENTS AND METHODS: We retrospectively analyzed ninety-three patients with recurrent advanced oral cancer from 2009 to 2013. Sixty-four patients are in the docetaxel with cisplatin and 5'-fluorouracil (TPF) group and the remaining twenty-nine patients are in the cisplatin and 5'-fluorouracil (PF) group. RESULTS: The overall response rate was better in the TPF group (p=0.005) than the PF group. Patients who received induction chemotherapy, TPF, followed by surgery and concurrent chemoradiotherapy (CRT) had better overall survival (OS) (p=0.012) and progression-free survival (PFS) (p=0.038), while patients with prior intra-arterial-infusion-chemotherapy had an adverse impact on OS (p=0.039). CONCLUSION: We showed that induction chemotherapy with TPF, followed by surgery and consolidation CRT, is the ideal choice for recurrent advanced HNSCC with improving response rates and survival. However, prior intra-arterial-infusion-chemotherapy showed an adverse impact. Copyright
BACKGROUND: Locally recurrent rate of advanced head and neck squamous cell carcinoma (HNSCC) still remains high and the treatment is controversial. PATIENTS AND METHODS: We retrospectively analyzed ninety-three patients with recurrent advanced oral cancer from 2009 to 2013. Sixty-four patients are in the docetaxel with cisplatin and 5'-fluorouracil (TPF) group and the remaining twenty-nine patients are in the cisplatin and 5'-fluorouracil (PF) group. RESULTS: The overall response rate was better in the TPF group (p=0.005) than the PF group. Patients who received induction chemotherapy, TPF, followed by surgery and concurrent chemoradiotherapy (CRT) had better overall survival (OS) (p=0.012) and progression-free survival (PFS) (p=0.038), while patients with prior intra-arterial-infusion-chemotherapy had an adverse impact on OS (p=0.039). CONCLUSION: We showed that induction chemotherapy with TPF, followed by surgery and consolidation CRT, is the ideal choice for recurrent advanced HNSCC with improving response rates and survival. However, prior intra-arterial-infusion-chemotherapy showed an adverse impact. Copyright